Avacta RNS releases

Avacta CEO Dr Alastair Smith 'encouraged' by first commercial Affimer deal

Dr Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ) tells Proactive they're at an “important value inflection point” after validating the commercial potential of its Affimer technology. It follows the successful evaluation of its technology by a “large, global diagnostics developer”. This has led the partner...

Avacta Group boss talks through 'excellent' Affimer study results

Avacta Group Plc ( LON:AVCT ) has described as “excellent” results from the latest study of its Affimer technology, which it said is now at an “inflection point” as a therapeutic platform. Chief Executive Dr Alastair Smith tells Proactive he's delighted with the results which show that none of the Affimer scaffolds induce a...

Pages